ARTICLE | Financial News
ORIC raises $55M to fund trials in drug-resistant cancers
August 9, 2019 12:03 AM UTC
With a $55 million series D round and recent hires from Ignyta and Genentech, ORIC believes it has the money and the team to advance multiple drug-resistant cancer therapies through clinical studies.
ORIC Pharmaceuticals Inc. (South San Francisco, Calif.), which has now raised more than $175 million, was founded by the duo behind Aragon Pharmaceuticals and its spinout Seragon Pharmaceuticals -- Charles Sawyers and Richard Heyman...